top of page
Browse by category
Search
Altimmune completes dosing in the Phase 2 MOMENTUM trial
Altimmune has completed dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of...
Altimmune begins MOMENTUM obesity trial for Pemvidutide
Altimmune has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide in...
Browse by tag
bottom of page